Bio News
Yuhan Corp. has signed a 131 billion won supply agreement for active pharmaceutical ingredients (API) with a global pharmaceutical company. The contract is valued at $95.42 million (approximately 131 billion won), equivalent to 6.0% of its most recent revenue. The contract runs from Sept. 1, 2026, through May 31, 2028.
Biobook Team
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
